| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.08(B) |
| Last
Volume: |
2,144,916 |
Avg
Vol: |
1,949,015 |
| 52
Week Range: |
$44.82 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,762 |
108,398 |
166,494 |
290,334 |
| Total Sell Value |
$463,948 |
$6,570,910 |
$11,277,891 |
$18,676,003 |
| Total People Sold |
8 |
10 |
11 |
11 |
| Total Sell Transactions |
11 |
52 |
61 |
100 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carey Thomas D. |
Director |
– • – |
2017-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,723 |
58,358 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2017-05-09 |
4 |
GD |
$0.00 |
$0 |
I/I |
13,706 |
0 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2017-05-01 |
4 |
A |
$13.26 |
$14,732 |
D/D |
1,111 |
1,111 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-05-01 |
4 |
A |
$5.95 |
$21,247 |
D/D |
3,571 |
334,727 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-05-01 |
4 |
A |
$5.95 |
$21,247 |
D/D |
3,571 |
820,810 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2017-04-03 |
4 |
AS |
$23.74 |
$36,631 |
D/D |
(1,543) |
53,935 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2017-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,688 |
55,478 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2017-03-13 |
4 |
AS |
$21.16 |
$117,946 |
D/D |
(5,574) |
556,339 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2017-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,025 |
52,773 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,425 |
334,101 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,400 |
829,298 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2017-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,275 |
561,913 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-02-27 |
4 |
AS |
$21.48 |
$420,084 |
D/D |
(19,557) |
804,898 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2017-02-27 |
4 |
AS |
$21.48 |
$181,549 |
D/D |
(8,452) |
550,638 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2017-02-27 |
4 |
AS |
$21.48 |
$151,348 |
D/D |
(7,046) |
46,748 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-02-27 |
4 |
AS |
$21.48 |
$128,901 |
D/D |
(6,001) |
325,676 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,025 |
824,455 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2017-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,150 |
559,090 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2017-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,400 |
53,794 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,900 |
331,677 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,500 |
804,430 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-02-24 |
4 |
AS |
$21.57 |
$163,436 |
D/D |
(7,577) |
784,930 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2017-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,000 |
546,940 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2017-02-24 |
4 |
AS |
$21.57 |
$57,419 |
D/D |
(2,662) |
535,940 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,250 |
322,777 |
|
- |
|
777 Records found
|
|
Page 24 of 32 |
|
|
0.20 (0.44%) 
